Newsroom | 5325 results

MANHASSET, N.Y.--(BUSINESS WIRE)--Neuropathic pain affects up to 10 percent of the global population and can be challenging to manage effectively with existing medications. As a possible alternative treatment option, scientists at Northwell Health’s Feinstein Institutes for Medical Research have discovered that ultrasound precisely targeted at the spinal cord can reduce neuropathic pain and neuroinflammation in preclinical models. The study – published today in Bioelectronic Medicine, an open-a...

CHELMSFORD, Mass.--(BUSINESS WIRE)--The Cannabist Company Holdings Inc. (Cboe CA: CBST) (OTCQX: CBSTF) (FSE: 3LP) (“The Cannabist Company” or the “Company”), one of the most experienced cultivators, manufacturers and retailers of cannabis products in the U.S., announced today that the Ontario Superior Court of Justice (Commercial List) (the “Court”) has granted an interim order (the “Interim Order”) authorizing various matters in connection with the Company’s plan of arrangement (the “Plan”) un...

LOS ANGELES--(BUSINESS WIRE)--Next Health and Sunlife Organics launch the “Limitless” superfood smoothie—packed with functional ingredients to energize and fuel vibrant living....

DUBLIN--(BUSINESS WIRE)--The "United States Home Infusion Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" report has been added to ResearchAndMarkets.com's offering. The United States home infusion therapy market is projected to reach approximately US$ 20.59 billion by 2033, up from US$ 10.26 billion in 2024, with a compound annual growth rate (CAGR) of 8.05% from 2025 to 2033. This growth is driven by the increasing prevalence of chronic diseases, advancements in...

LOS ANGELES--(BUSINESS WIRE)--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the broadening of its NAD+ precursor intellectual property (IP) portfolio with the newly granted U.S. Patent 12,252,506, which covers the composition of matter for nicotinamide riboside (NR) salt forms, including NR Malate and NR Tartrate, and other NR derivatives. This is p...

LOS ANGELES--(BUSINESS WIRE)--Niagen Bioscience, Inc. (Nasdaq: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today confirmed it has changed its corporate name to Niagen Bioscience, Inc. (“Niagen Bioscience” or the “Company”) and the Company’s common stock will begin trading under the new Nasdaq symbol “NAGE” at stock market open today, Wednesday, March 19, 2025. The CUSIP number for the Company's...

KYLE, Texas--(BUSINESS WIRE)--ProCare, a Texas-based accident and injury-focused medical group, today announced the grand opening of its newest clinic in Kyle, Texas....

BERLIN--(BUSINESS WIRE)--The International Cannabis Business Conference (ICBC) announced today details of its upcoming 2025 flagship conference in Berlin. The April 29-30 event at the iconic Estrel Berlin hotel will include an expo, a conference and major networking opportunities for business leaders and entrepreneurs, with Germany moving to the forefront of the global cannabis industry spotlight after its passage of transformative law reforms. “Europe is currently by far the most exciting plac...

LOWELL, Mass.--(BUSINESS WIRE)--RevBio, Inc., announced that it has received regulatory and ethics committee approvals in multiple European countries to conduct its pivotal clinical trial for its dental implant stabilization product. The successful completion of this pivotal clinical trial will result in the CE marking approval for the product, which will allow the company to begin commercial sales in Europe. As of the date of this press release, the company has already enrolled 30 of an expect...

米国サンディエゴ--(BUSINESS WIRE)--（ビジネスワイヤ） -- 米国カリフォルニア州サンディエゴに本社を置き、JSR Life SciencesおよびJSR株式会社傘下の世界的医薬品開発業務受託機関（CRO）であるCrown Bioscienceは、John Guを新しい最高経営責任者 (CEO) に任命しました。暫定 CEO としての在任期間と最高執行責任者 (COO) としての役割を経て、John Gu は幅広いビジネス洞察力とデジタル戦略、ビジネス変革、ゲノムデータ分析における豊富な経験を持つ尊敬されるリーダーとして認められています。彼の類まれなる経験は、創薬および開発プロセスを推進するための AI 主導のアプローチの合理化にとりわけ関連しており、Crown Bioscienceをバイオテクノロジー革新の最前線に導く上で尽力をつくしてきた人材です。 Crown Bioscienceの親会社であるJSR Life SciencesのTim Lowery社長は、「Gu氏のグローバルな視点とコラボレーションと卓越性への取り組みは、ビジョンを持ったリーダーシップのための...